The UCSF validation study confirmed that 100% of patients with TIL containing less than 20% PD-1/CTLA-4 phenotype will not respond to anti-PD-1 monotherapy. Their inductive post hoc analysis was the exploratory study that established the TIL biomarker hypothesis, and the validation study produced confirmation of the biomarker cutoffs and predictive values. This was all reported in August.
News 
Market Data 
Discover 
